Inhibitor-immunology-study ||| S:0 E:26 ||| NNP
.  ||| S:26 E:28 ||| .
Evaluation  ||| S:28 E:39 ||| NN
of  ||| S:39 E:42 ||| IN
inhibitor  ||| S:42 E:52 ||| JJ
development  ||| S:52 E:64 ||| NN
in  ||| S:64 E:67 ||| IN
haemophilia  ||| S:67 E:79 ||| JJ
B  ||| S:79 E:81 ||| NN
The  ||| S:81 E:85 ||| DT
development  ||| S:85 E:97 ||| NN
of  ||| S:97 E:100 ||| IN
inhibitors  ||| S:100 E:111 ||| NN
in  ||| S:111 E:114 ||| IN
haemophilia  ||| S:114 E:126 ||| JJ
B  ||| S:126 E:128 ||| NNP
is  ||| S:128 E:131 ||| VBZ
one  ||| S:131 E:135 ||| CD
of  ||| S:135 E:138 ||| IN
the  ||| S:138 E:142 ||| DT
most  ||| S:142 E:147 ||| RBS
important  ||| S:147 E:157 ||| JJ
complications  ||| S:157 E:171 ||| NNS
of  ||| S:171 E:174 ||| IN
replacement  ||| S:174 E:186 ||| NN
therapy ||| S:186 E:193 ||| NN
,  ||| S:193 E:195 ||| ,
affecting  ||| S:195 E:205 ||| VBG
mortality  ||| S:205 E:215 ||| NN
and  ||| S:215 E:219 ||| CC
morbidity ||| S:219 E:228 ||| NN
.  ||| S:228 E:230 ||| .
Inhibitor  ||| S:230 E:240 ||| JJ
development  ||| S:240 E:252 ||| NN
is  ||| S:252 E:255 ||| VBZ
based  ||| S:255 E:261 ||| VBN
on  ||| S:261 E:264 ||| IN
complex  ||| S:264 E:272 ||| JJ
immunological  ||| S:272 E:286 ||| JJ
factors ||| S:286 E:293 ||| NNS
,  ||| S:293 E:295 ||| ,
and  ||| S:295 E:299 ||| CC
to  ||| S:299 E:302 ||| TO
date ||| S:302 E:306 ||| NN
,  ||| S:306 E:308 ||| ,
only  ||| S:308 E:313 ||| RB
little  ||| S:313 E:320 ||| RB
is  ||| S:320 E:323 ||| VBZ
known  ||| S:323 E:329 ||| VBN
about  ||| S:329 E:335 ||| IN
its  ||| S:335 E:339 ||| PRP$
underlying  ||| S:339 E:350 ||| JJ
mechanisms ||| S:350 E:360 ||| NNS
.  ||| S:360 E:362 ||| .
Here ||| S:362 E:366 ||| RB
,  ||| S:366 E:368 ||| ,
we  ||| S:368 E:371 ||| PRP
present  ||| S:371 E:379 ||| VBP
first  ||| S:379 E:385 ||| JJ
results  ||| S:385 E:393 ||| NNS
of  ||| S:393 E:396 ||| IN
the  ||| S:396 E:400 ||| DT
haemophilia  ||| S:400 E:412 ||| JJ
B  ||| S:412 E:414 ||| NN
group  ||| S:414 E:420 ||| NN
of  ||| S:420 E:423 ||| IN
our  ||| S:423 E:427 ||| PRP$
Inhibitor-Immunology  ||| S:427 E:448 ||| JJ
study ||| S:448 E:453 ||| NN
.  ||| S:453 E:455 ||| .
So  ||| S:455 E:458 ||| RB
far  ||| S:458 E:462 ||| RB
we  ||| S:462 E:465 ||| PRP
have  ||| S:465 E:470 ||| VBP
analysed  ||| S:470 E:479 ||| RB
15  ||| S:479 E:482 ||| CD
patients  ||| S:482 E:491 ||| NNS
with  ||| S:491 E:496 ||| IN
haemophilia  ||| S:496 E:508 ||| JJ
B.  ||| S:508 E:511 ||| NNP
Four  ||| S:511 E:516 ||| CD
of  ||| S:516 E:519 ||| IN
them  ||| S:519 E:524 ||| PRP
developed  ||| S:524 E:534 ||| VBD
a  ||| S:534 E:536 ||| DT
high  ||| S:536 E:541 ||| JJ
titre  ||| S:541 E:547 ||| JJ
inhibitor ||| S:547 E:556 ||| NN
;  ||| S:556 E:558 ||| :
the  ||| S:558 E:562 ||| DT
remaining  ||| S:562 E:572 ||| JJ
11  ||| S:572 E:575 ||| CD
had  ||| S:575 E:579 ||| VBD
no  ||| S:579 E:582 ||| DT
inhibitor ||| S:582 E:591 ||| NN
.  ||| S:591 E:593 ||| .
We  ||| S:593 E:596 ||| PRP
evaluated  ||| S:596 E:606 ||| VBD
9  ||| S:606 E:608 ||| CD
SNPs  ||| S:608 E:613 ||| NN
in  ||| S:613 E:616 ||| IN
8  ||| S:616 E:618 ||| CD
genes  ||| S:618 E:624 ||| NNS
( ||| S:624 E:625 ||| -LRB-
CD40 ||| S:625 E:629 ||| NNP
,  ||| S:629 E:631 ||| ,
CTLA-4  ||| S:631 E:638 ||| NNP
,  ||| S:638 E:640 ||| ,
IL-1β ||| S:640 E:645 ||| NNP
,  ||| S:645 E:647 ||| ,
IL-10 ||| S:647 E:652 ||| NNP
,  ||| S:652 E:654 ||| ,
TLR2  ||| S:654 E:659 ||| NNP
,  ||| S:659 E:661 ||| ,
TLR4 ||| S:661 E:665 ||| NNP
,  ||| S:665 E:667 ||| ,
TLR9 ||| S:667 E:671 ||| NNP
,  ||| S:671 E:673 ||| ,
TNF-α ||| S:673 E:678 ||| NNP
) ||| S:678 E:679 ||| -RRB-
.  ||| S:679 E:681 ||| .
We  ||| S:681 E:684 ||| PRP
compared  ||| S:684 E:693 ||| VBD
the  ||| S:693 E:697 ||| DT
distribution  ||| S:697 E:710 ||| NN
of  ||| S:710 E:713 ||| IN
these  ||| S:713 E:719 ||| DT
alleles  ||| S:719 E:727 ||| NN
between  ||| S:727 E:735 ||| IN
inhibitor  ||| S:735 E:745 ||| NN
and  ||| S:745 E:749 ||| CC
non-inhibitor  ||| S:749 E:763 ||| JJ
haemophilia  ||| S:763 E:775 ||| JJ
B  ||| S:775 E:777 ||| NN
patients  ||| S:777 E:786 ||| NNS
and  ||| S:786 E:790 ||| CC
between  ||| S:790 E:798 ||| IN
haemophilia  ||| S:798 E:810 ||| JJ
B  ||| S:810 E:812 ||| NN
patients  ||| S:812 E:821 ||| NNS
and  ||| S:821 E:825 ||| CC
a  ||| S:825 E:827 ||| DT
normal  ||| S:827 E:834 ||| JJ
male  ||| S:834 E:839 ||| JJ
control  ||| S:839 E:847 ||| NN
population ||| S:847 E:857 ||| NN
.  ||| S:857 E:859 ||| .
HLA  ||| S:859 E:863 ||| NNP
typing  ||| S:863 E:870 ||| NN
was  ||| S:870 E:874 ||| VBD
performed  ||| S:874 E:884 ||| VBN
in  ||| S:884 E:887 ||| IN
all  ||| S:887 E:891 ||| DT
patients ||| S:891 E:899 ||| NNS
.  ||| S:899 E:901 ||| .
Results ||| S:901 E:908 ||| NNS
,  ||| S:908 E:910 ||| ,
discussion ||| S:910 E:920 ||| NN
:  ||| S:920 E:922 ||| :
There  ||| S:922 E:928 ||| EX
appears  ||| S:928 E:936 ||| VBZ
to  ||| S:936 E:939 ||| TO
be  ||| S:939 E:942 ||| VB
a  ||| S:942 E:944 ||| DT
trend  ||| S:944 E:950 ||| NN
towards  ||| S:950 E:958 ||| IN
a  ||| S:958 E:960 ||| DT
skewed  ||| S:960 E:967 ||| JJ
distribution  ||| S:967 E:980 ||| NN
of  ||| S:980 E:983 ||| IN
TLR  ||| S:983 E:987 ||| NNP
9 ||| S:987 E:988 ||| CD
,  ||| S:988 E:990 ||| ,
IL-10  ||| S:990 E:996 ||| NNP
and  ||| S:996 E:1000 ||| CC
CTLA4  ||| S:1000 E:1006 ||| CD
alleles  ||| S:1006 E:1014 ||| NN
in  ||| S:1014 E:1017 ||| IN
haemophilia  ||| S:1017 E:1029 ||| JJ
B  ||| S:1029 E:1031 ||| NN
patients ||| S:1031 E:1039 ||| NNS
.  ||| S:1039 E:1041 ||| .
Due  ||| S:1041 E:1045 ||| JJ
to  ||| S:1045 E:1048 ||| TO
the  ||| S:1048 E:1052 ||| DT
limited  ||| S:1052 E:1060 ||| JJ
number  ||| S:1060 E:1067 ||| NN
these  ||| S:1067 E:1073 ||| DT
differences  ||| S:1073 E:1085 ||| NNS
are ||| S:1085 E:1088 ||| VBP
,  ||| S:1088 E:1090 ||| ,
however ||| S:1090 E:1097 ||| RB
,  ||| S:1097 E:1099 ||| ,
not  ||| S:1099 E:1103 ||| RB
statistically  ||| S:1103 E:1117 ||| RB
significant ||| S:1117 E:1128 ||| JJ
.  ||| S:1128 E:1130 ||| .
The  ||| S:1130 E:1134 ||| DT
t-test  ||| S:1134 E:1141 ||| JJ
of  ||| S:1141 E:1144 ||| IN
all  ||| S:1144 E:1148 ||| DT
patients  ||| S:1148 E:1157 ||| NNS
with  ||| S:1157 E:1162 ||| IN
inhibitor  ||| S:1162 E:1172 ||| JJ
versus  ||| S:1172 E:1179 ||| NN
without  ||| S:1179 E:1187 ||| IN
inhibitor  ||| S:1187 E:1197 ||| NN
was  ||| S:1197 E:1201 ||| VBD
significant  ||| S:1201 E:1213 ||| JJ
for  ||| S:1213 E:1217 ||| IN
HLA-A*03  ||| S:1217 E:1226 ||| NNP
and  ||| S:1226 E:1230 ||| CC
DPB1*0401  ||| S:1230 E:1240 ||| NNP
and  ||| S:1240 E:1244 ||| CC
borderline  ||| S:1244 E:1255 ||| NN
for  ||| S:1255 E:1259 ||| IN
DRB1*0201 ||| S:1259 E:1268 ||| CD
.  ||| S:1268 E:1270 ||| .
